Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals Plc ADR (NQ: CNTA )

13.17 +0.13 (+1.00%)
Streaming Delayed Price Updated: 9:50 AM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Centessa Pharmaceuticals Plc ADR

< Previous 1 2 3 Next >
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 02/14/2023 -- An investigation was announced for investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) concerning potential breaches of fiduciary duties by... 
Via SBWire
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
NASDAQ: CNTA Investor Alert: Deadline on November 28, 2022 in Lawsuit against Centessa Pharmaceuticals plc
San Diego, CA -- (SBWIRE) -- 11/28/2022 -- 
Via SBWire
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody being developed for solid tumors 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Centessa Pharmaceuticals plc (CNTA) Investors of Class Action Deadline and Encourages Investors to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
CENTESSA PHARMACEUTICALS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
From Kahn Swick & Foti, LLC
Via Business Wire
CENTESSA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentation 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Barclays, Warner Bros., Olo, and Centessa and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Notifies Centessa Pharmaceuticals plc (CNTA) Investors of Class Action and Encourages Investors to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NASDAQ:CNTA Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Centessa Pharmaceuticals Plc
San Diego, CA -- (SBWIRE) -- 10/12/2022 -- An investor, who purchased shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA), filed a lawsuit against Centessa Pharmaceuticals plc over alleged Federal... 
Via SBWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa and PayPal and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/05/2022 -- An investigation on behalf of investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) was announced over potential breaches of fiduciary duties by... 
Via SBWire
INVESTOR NOTICE: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CNTA
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.